Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors

Purpose Anticancer agents are known to increase cancer-associated thrombosis (CAT) onset. CAT onset rate is reported to be 1.92% in cisplatin-based therapy, 6.1% in paclitaxel plus ramucirumab combination therapy, and 11.9% in bevacizumab monotherapy. Because immune checkpoint inhibitors (ICIs) caus...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, Yosuke, Hayashi, Takahiro, Sugimoto, Reiko, Nishibe, Seira, Ito, Kaori, Kawada, Kenji, Ikeda, Yoshiaki, Yamada, Shigeki, Imaizumi, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340643/
https://www.ncbi.nlm.nih.gov/pubmed/31823160
http://dx.doi.org/10.1007/s10637-019-00881-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340643/
https://www.ncbi.nlm.nih.gov/pubmed/31823160
http://dx.doi.org/10.1007/s10637-019-00881-6

Ejemplares similares